6600.HK Stock Analysis
66
Uncovered
SciClone Pharmaceuticals (Holdings) Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
SciClone Pharmaceuticals (Holdings) Ltd. is an investment holding company which manufactures and markets immune and oncology pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 770 full-time employees. The company went IPO on 2021-03-03. The firm primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.